Pharmacokinetic and pharmacodynamic study of a new nonsteroidal 5α- reductase inhibitor, 4-[3-[3-[Bis(4-isobutylphenyl)methylamino]benzoyl]-1H- indol-1-yl]-butyric acid, in rats

Journal of Pharmacology and Experimental Therapeutics

Volumn 284, Issue 3, 1998, Pages 914-920

  Katashima, Masataka ^a   Yamamoto, Koujirou ^b   Tokuma, Yoji ^a   Hata, Takehisa ^a   Sawada, Yasufumi ^c   Iga, Tatsuji ^b  

^a ASTELLAS PHARMA INC   (Japan)

^b UNIVERSITY OF TOKYO HOSPITAL   (Japan)

^c KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

4 [3 [3 [BIS(4 ISOBUTYLPHENYL)METHYLAMINO]BENZOYL] 1H INDOL 1 YL]BUTYRIC ACID; ANDROSTANOLONE; STEROID 5ALPHA REDUCTASE INHIBITOR;

ADOLESCENT; ANIMAL TISSUE; ARTICLE; BINDING KINETICS; CONTROLLED STUDY; DRUG BINDING; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG TISSUE LEVEL; ENZYME BINDING; INTRAVENOUS DRUG ADMINISTRATION; MALE; MODEL; NONHUMAN; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; RAT;

ANIMALS; DIHYDROTESTOSTERONE; ENZYME INHIBITORS; INDOLES; MALE; PHENYLBUTYRATES; RATS; RATS, SPRAGUE-DAWLEY; TESTOSTERONE 5-ALPHA-REDUCTASE;

EID: 0031910002     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Abalain JH, Quemener E, Carre JL, Simon B, Amet Y, Mangin P and Floch HH (1989) Metabolism of androgens in human hyperplastic prostate; Evidence for a differential location of the enzymes involved in the metabolism. J Steroid Biochem 34:467-471.
2. Anderson KM and Liao S (1968) Selective retention of dihydrotestosterone by prostatic nuclei. Nature 219:277-279.
3. Bruchovsky N and Wilson JD (1968a) The conversion of testosterone to 5α-androstan-17b-ol-3-one by rat prostate in vivo and in vitro. J Biot Chem 243:2012-2021.
4. Bruchovsky N and Wilson JD (1968b) The intranuclear binding of testosterone and 5α-androstan-17β-ol-3-one by rat prostate. J Biol Chem 243:5953-5960.
5. Fukabori Y, Takezawa Y, Yamanaka H and Honma S (1992) Inhibition of 3α-hydroxysteroid oxidoreductase and 5α-reductase activity by antiandrogens and indomethacin in the rat prostate. Prostate 21:255-267.
6. Gloyna RE, Siiteri PK and Wilson DJ (1970a) Dihydrotestosterone in prostatic hypertrophy, I. The formation and content of dihydrotestosterone in the hypertrophic prostate of man. J Clin Invest 49:1737-1745.
7. Gloyna RE, Siiteri PK and Wilson DJ (1970b) Dihydrotestosterone in prostatic hypertrophy, II. The formation and content of dihydrotestosterone on prostatic growth in the dog. J Clin Invest 49:1746-1753.
8. Haaparanta T, Gustafsson, Jan-Åke and Glaumann H (1983) Isolation of mitochondria, lysosome and microsomes from the rat ventral prostate with a note on inverted microsomal vesicles. Arch Biochem Biophys 223:458-467.
9. Hammond GL (1978) Endogenous steroid levels in the human prostate from birth to old age: A comparison of normal and diseased tissues. J Endocrinol 78:7-19.
10. Hirosumi J, Nakayama O, Fagan T, Sawada K, Chida N, Inami M, Takahashi S, Kojo. H, Notsu Y and Okuhara M (1995a) FK143, a novel nonsteroidal inhibitor of steroid 5α-reductase: (1) In vitro effects on human and animal prostatic enzymes. J Steroid Biochem Molec Biol 52:357-363.
11. Hirosumi J, Nakayama O, Chida N, Inami M, Fagan T, Sawada K, Shigematsu S, Kojo H, Notsu Y and Okuhara M (1995b) FK143, a novel nonsteroidal inhibitor of steroid 5α-reductase: (2) In vivo effects on rat and dog prostate. J Steroid Biochem Molec Biol 52:365-373.
12. Hudson RW, Moffitt PM and Owens WA (1982a) Studies of the nuclear 5α-reductase of human prostatic tissue: comparison of enzyme activities in hyperplastic, malignant and normal tissue. Can J Biochem Cell. Biol 61:750-755.
13. Hudson RW (1982b) Study of the cytosol 3α-hydroxysteroid dehydrogenase of human prostatic tissue: comparison of enzyme activities in hyperplastatic, malignant and normal tissues. J Steroid Biochem 16:373-377.
14. Isaacs JT and Coffey DS (1981) Changes in dihydrotestosterone metabolism associated with the development of canine benign prostatic hyperplasia. Endocrinology 108:445-453.
15. Katashima M, Yamamoto K, Sugiura M, Sawada Y and Iga T (1995) Comparative pharmacokinetic/pharmacodynamic study of proton pump inhibitors, omeprazole and lansoprazole in rats. Drug Metab Dispos 23:718-723.
16. Katashima M, Yamamoto K, Haraguchi K, Tokuma Y, Hata T, Sawada Y and Iga T (1997) Tissue distribution kinetics of a new non-steroidal testosterone 5α-reductase inhibitor, 4-[3-[3-[Bis(4-isobutylphenyl)methylamino]benzoyl]-1H-indol-1-yl]-butyric acid, in rats. Drug Metab Dispos 25:1051-1058.
17. Ko HC and Jusko WJ (1995) Pharmacodynamic modeling of Finasteride, a 5α-reductase inhibitor. Pharmacotherapy 15:509-511.
18. Liang T, Heiss CE, Ostrove S, Rasmusson GH and Cheung A (1983) Binding of a 4-methyl-4-aza-steroid to 5α-reductase of rat liver and prostate microsomes. Endocrinology 112:1460-1468.
19. Peters DH and Sorkin EM (1993) Finasteride-A review of its potential in the treatment of benign prostatic hyperplasia. Drugs 46:177-208.
20. Rittmaster RS (1994) Drug Therapy - Finasteride. N Engl J Med 330:120-125.
21. Sadano H and Omura T (1982) Turnover of different forms of microsomal cytochrome P-450 in rat liver, in Cytochrome P-450, Biochemistry, Biophysics and Environmental Implications (Hietanen E ed) pp 299-306: Elsevier/North Holland, Amsterdam.
22. Sandberg AA (1980) Endocrine control and physiology of the prostate. Prostate 1:169-184.
23. Steiner JF (1996) Clinical pharmacokinetics and pharmacodynamics of finasteride. Clin Pharmacokinet 30:16-27.
24. Sugiura M, Yamamoto K, Sawada Y and Iga T (1992) Prediction of therapeutic dose based on pharmacokinetic/pharmacodynamic model of omeprazole, a proton pump inhibitor. Xenobio Metab Dispos 7:813-820.
25. The Finasteride Study Group (1992) The effect of finasteride in men with benign prostatic hyperplasia. N Engl J Med 327:1185-1191.
26. Thijssen HHW and Janssen YPG (1994) Target-based warfarin pharmacokinetics in the rat: The link with the anticoagulant effect. J Pharmacol Exp Ther 270:554-558.
27. Yamamoto K, Abe M, Katashima M, Yamada Y, Sawada Y and Iga T (1996) Pharmacodynamic analysis of antiplatelet effect of aspirin in the literature-Modeling based on inhibition of cyclooxygenase in the platelet and the vessel wall endothelium. Jpn J Hasp Pharm 22:133-141.